Official Title

Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Study Participants

    175
Evaluation of the following in very young children with Down syndrome:

the efficacy of systematic treatment with L-thyroxine at controlled doses (clinically and by ultrasensitive thyreostimulating hormone (TSH) assay),
the efficacy of systematic folinic acid treatment at a dose of 1 mg/kg/o.i.d,
any interaction between these two treatments.
Study Started
Apr 02
2012
Primary Completion
Dec 14
2017
Study Completion
Dec 14
2017
Results Posted
May 13
2020
Last Update
May 13
2020

Drug thyroid hormone and folinic acid

thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules

Thyroxin + folinic acid Experimental

Thyroxin+folinic acid placebo Active Comparator

Thyroxin placebo+ folinic acid Active Comparator

Thyroxin placebo+ folinic acid placebo Placebo Comparator

Criteria

Inclusion Criteria:

patient with a karyotype demonstrating homogeneous, free or Robertsonian translocation trisomy 21
patient having undergone a cardiac ultrasound not demonstrating any severe heart disease
patient aged 6 to 18 months at inclusion

Exclusion Criteria:

congenital hypothyroidism
hypothyroidism demonstrated by laboratory tests (TSH > 7mUI/l)
presenting or having presented hyperthyroidism
presenting or having presented leukaemia
presenting or having presented West syndrome or any other form of epilepsy or unstable neurological disease
presenting or having presented signs of central nervous system distress: stroke, postoperative hypoxia, meningitis)
presenting severe heart disease on cardiac ultrasound, with haemodynamic effects
presenting non-controlled cardiac arrhythmia
Apgar < 7 to 5 min at birth
Gestational age < 231 days (33 gestation weeks)

Summary

Thyroxin+Folinic Acid Placebo

Thyroxin + Folinic Acid

Thyroxin Placebo+ Folinic Acid

Thyroxin Placebo+ Folinic Acid Placebo

All Events

Event Type Organ System Event Term Thyroxin+Folinic Acid Placebo Thyroxin + Folinic Acid Thyroxin Placebo+ Folinic Acid Thyroxin Placebo+ Folinic Acid Placebo

GMDS (Griffiths Mental Development Scale)

GMDS for testing and estimate babies psychomotor development from birth to 2 years trough six subscales : Locomotor, Personal-social, Hearing and language, Eye-Hand coordination, Performance.Sub- and General Quotients (GDQ) standard score are based on a mean of 100 and a standard deviation of 16. For children with delayed development, which is the case for children with Down Syndrome, Quotient tables could be not used because sub- and General quotient floors at 50. For each subscale, a raw score was derived from the contributing items. Total raw score was obtained by adding subscale raw scores. Sum of all subscale raw scores was converted into a development age using correspondence table. Subscale and global development quotients were computed by dividing the development age by the chronological age multiplied by 100. For preterm infants, chronological age was corrected taking into account the gestational term. Higher QD's scores show a better psychomotor development outcome

Thyroxin + Folinic Acid

51.96
developpement quotient (Mean)
Standard Deviation: 7.88

Thyroxin+Folinic Acid Placebo

51.27
developpement quotient (Mean)
Standard Deviation: 6.48

Thyroxin Placebo+ Folinic Acid

51.66
developpement quotient (Mean)
Standard Deviation: 6.37

Thyroxin Placebo+ Folinic Acid Placebo

51.67
developpement quotient (Mean)
Standard Deviation: 8.29

BL (Brunet Lezine Revised Scale)

BL includes 4 subscales : Locomotor, Coordination, Language, Sociability. Subscale and global developpemental quotients were computed by dividing the developpemental age by the chronological age multiplied by 100. This kind of formula do not give a min-max outcome. Higher QD's scores show a better psychomotor developpement outcome.

Thyroxin + Folinic Acid

51.18
developpement quotient (Mean)
Standard Deviation: 6.98

Thyroxin+Folinic Acid Placebo

50.64
developpement quotient (Mean)
Standard Deviation: 7.25

Thyroxin Placebo+ Folinic Acid

51.24
developpement quotient (Mean)
Standard Deviation: 6.46

Thyroxin Placebo+ Folinic Acid Placebo

51.36
developpement quotient (Mean)
Standard Deviation: 8.27

Total

156
Participants

Patient's head circumference at baseline

43.63
cm (Mean)
Standard Deviation: 1.6

Patient's height at baseline

71.21
cm (Mean)
Standard Deviation: 4.33

Patient's weight at baseline

8.42
Kg (Mean)
Standard Deviation: 1.35

Pregnancy term

38.07
weeks of amenorrhea (Mean)
Standard Deviation: 1.18

Race and Ethnicity Not Collected

0
Participants

TSH

4.46
mIU/L (Mean)
Standard Deviation: 1.5

Age, Customized

Cardiac abnormalities

Karyotype %

Region of Enrollment

Sex: Female, Male

Overall Study

Thyroxin + Folinic Acid

Thyroxin+Folinic Acid Placebo

Thyroxin Placebo+ Folinic Acid

Thyroxin Placebo+ Folinic Acid Placebo

Drop/Withdrawal Reasons

Thyroxin + Folinic Acid

Thyroxin+Folinic Acid Placebo

Thyroxin Placebo+ Folinic Acid

Thyroxin Placebo+ Folinic Acid Placebo